【摘要】 基于较高的靶本比(TBR)，靶向成纤维细胞激活蛋白(FAP)新型显像剂在多种肿瘤中表现出较好的显像效果。近年来，随着研究的深入，FAP的抑制剂(FAPI)在肿瘤显像与治疗中显示出了巨大的应用前景，其可以作为主流代谢显像剂氟-18标记氟代脱氧葡萄糖(18F-FDG)的补充，为未来肿瘤代谢和肿瘤间质可视化的更高效结合提供了可能，有助于更准确地指导临床诊断与治疗。文章主要综述了FAP新型显像剂在多种肿瘤中的应用情况，将其与现有的放射诊断手段进行了比较，重点总结了特异性靶向FAPI的示踪剂在肿瘤及非特异性组织中的临床应用进展及未来潜力。

    【关键词】 成纤维细胞激活蛋白；放射性同位素；靶向制剂； 肿瘤

    Advances in novel imaging agents targeting fibroblast activation proteins

    WANG Ning1，2， SHI Yizhen 1

    (1.Department of Nuclear Medicine， the Second Affiliated Hospital of Soochow University， Suzhou 215004， China；

    2.Shanghai Key Laboratory of Molecular Imaging/Shanghai University of Medicine and Health Sciences， Shanghai 201308， China)

    Corresponding author： SHI Yizhen， E-mail： shiyizhen@suda.edu.cn

    【Abstract】 Based on the high target-to-background ratio (TBR)， new imaging agents targeting fibroblast activation protein (FAP) have shown better imaging effects in a variety of tumors. In recent years， with in-depth research， FAP inhibitor (FAPI) has shown great application prospects in tumor imaging and treatment. It can be used as a supplement to the mainstream metabolic imaging agent 18F-labeled fluorodeoxyglucose (18F-FDG) ......